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The use of reduced intensity conditioning with total lymphocyte
irradiation (TLI) and anti-thymocyte globulin (ATG) in preparation
for allogeneic transplantation has been shown to minimize the risk of
GVHD through biasing of T cell reconstitution towards an inhibi-
tory phenotype.However, disease relapse remains a concern. Clofar-
abine (Clo) is a second generation nucleoside analog with efficacy in
hematological malignancies. In this study, we examined the combi-
nation of Clo, TLI and ATG with respect to T cell reconstitution
and transplant outcomes. Sequential cohorts of 5 patients were
treated with TLI and ATG alone or in conjunction with 20 mg/
m2, 30 mg/m2 or 40 mg/m2 of Clo for 5 days. Twenty patients
have been enrolled (5 AML/MDS, 2 ALL, 6 lymphoma, 2 CLL, 5
myeloma) and received HLA matched peripheral blood stem cells
from related (N5 11) or unrelated donors (N5 9). Of 19 evaluable
patients, 15 are alive with a median follow up of 665 days. Day 100
mortality was 0% for TLI and ATG and 10% for those receiving
Clo. The maximum tolerated dose (MTD) of Clo was 30 mg/m2.
Mean bone marrow donor chimerism was 92.5% at Day 30. T cell
reconstitution studies demonstrated a decrease in CD4+ cells to
\200 cells/uL persisting for more than 6 months, and a more than
two fold increase in circulating CD56+ NK cells. No significant de-
crease in CD8 T cells in the early post-transplant period was seen.
The mean percentage of regulatory T cells (CD4+/25+/FoxP3+)
rose in the early post-transplant period following TLI and ATG
(5.5 to 14.2% from baseline to day 30; p 5 0.015), but not in those
receiving Clo (8.1 to 6%; p 5 0.15). A two fold increase in CD8+
T cells expressing IL-4 was seen at Day 30 in patients receiving
TLI and ATG alone (p 5 0.04); but not following Clo, TLI and
ATG. Consistent with these findings, the incidence of grade II-IV
GVHD was 0% and 42% in those receiving TLI and ATG alone
or with Clo, respectively. cGVHD was seen in 20% and 42% of pa-
tients, respectively. In contrast, disease progression was seen in 60%
of patients receiving TLI and ATG alone as compared to 27% re-
ceiving Clo, TLI, and ATG. In summary, the addition of Clo to
TLI and ATG conditioning resulted in a decrease in circulating reg-
ulatory T cells, decreased CD8+ T cell expression of IL-4, and was
associated with an increased risk of GVHD and the potential de-
crease in the risk of relapse in this pilot study.28
FAVORABLE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT IN
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CIBMTR has reported that severe thalassemia patients who were
older than 7 years and hepatomegaly, had poor outcome of trans-
plantation (DFS 5 55%) (Blood; 2011). We therefore would like
to report our new approach of transplant for this group of patients
with our reduced intensity conditioning regimen (RIC). We re-
viewed 20 severe thalassemia patients older than 10 years and hepa-
tomegaly (liver 2 cm below coastal margin). These patients
underwent transplantation with our RIC which consisted of busul-
fan, fludarabine, antithymocyte globulin, 6 TLI. All patients re-
ceived peripheral blood stem cells. Prior to transplant, all of them
at least for 1 year went on a pre-transplant management program in-
cluding hypertransfusion, iron chelation and oral hydroxyurea. We
also conducted a post transplant management by using chimerism
study followed by various strategies such as reducing immusuppres-sive drug and infusing donor lymphocyte or peripheral blood setm
cell to prevent further graft loss in case of mixed chimersim within
the first 100 days after transplant. Of 20 patients, 17 received related
and 3 received unrelated donor stem cells. Thalassemia free and
overall survivals were 92%. The rejection and mortality rates were
8%.We suggest that our high risk severe thalassemia can acheive a fa-
vorable outcome of transplant with our RIC approach especially our
pre and post transplant management.29
SHORT-TERM IMMUNOSUPPRESSIVE AGENTS FOR GRAFT-VERSUS-HOST
DISEASE (GVHD) PROPHYLAXIS AFTER DONOR LYMPHOCYTE INFUSION
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Background:The use of graft-versus-host disease (GVHD) prophy-
laxis after donor lymphocyte infusion (DLI) could reduce the inci-
dence of severe DLI-associated acute GVHD in haploidentical
hematopoietic stem cell transplantation (HSCT), but the influence
of GVHD prophylaxis on the graft-versus-leukemia (GVL) effects
has not been investigated.
Methods: 158 patients receiving DLI after haploidentical HSCT
were enrolled. Specifically, 46 received therapeutic DLI because of
hematological or extramedullary relapse after HSCT; 46 received
pre-emptive DLI because of minimal residual disease (MRD) after
HSCT; and 66 received prophylactic DLI because of a high-risk dis-
ease status pre-HSCT.
Results: Compared with using GVHD prophylaxis 4 - 6 weeks and
less than 4 weeks, prophylaxis more than 6 weeks had no influence on
relapse after DLI (2-year: 24.2%, 42.3% and 45.6%, P5 0.106) and
resulted in superior overall survival (2-year OS: 53.4%, 34.5% and
29.2%, P 5 0.037) and leukaemia-free survival (2-year LFS:
45.2%, 32.1% and 26.1%, P 5 0.043). Furthermore, whether for
pre-emptive or prophylactic DLI, there were trends that OS (pre-
emptive (2-year): 66.7%, 44.4% and 40.7%, P5 0.754; prophylactic
(2-year): 54.9%, 30.5% and 10.1%, P 5 0.013) and LFS (pre-emp-
tive (2-year): 66.7%, 38.9% and 39.7%, P 5 0.568; prophylactic
(2-year): 30.0%, 29.7% and 8.7%, P 5 0.042) in patients with pro-
phylaxis for more than 6 weeks were all superior to that in other pa-
tients. For therapeutic DLI, there was also a trend that the 1-year OS
in patients with prophylaxis for more than 6 weeks was superior to
that in other patients (50.0%, 28.6% and 39.2%, P 5 0.986) and
the 1-year LFS was similar to the result in other patietns (25.0%,
21.4% and 29.9%, P 5 0.785).
Conclusion: This study for the first time demonstrated that in
HLA-haploidentical HSCT, DLI with GVHD prophylaxis for
more than 6 weeks have no influence on GVL effects at the same
time could reduceDLI-associated acuteGVHD, and finally improve
survival.30
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Introduction: PNH is a debilitating and life-threatening hemato-
poietic stem cell disorder characterized by chronic hemolysis leading
to significant morbidities, end organ damage and mortality in PNH
patients. Even though there are different therapeutic approaches for
PNH, allotransplantation can cure the disease but cause several
